跳至主要内容
临床试验/NL-OMON39121
NL-OMON39121已完成不适用

Assessment of Comorbidities in COPD in European Symptomatic Subjects from primary care. - ACCESS

GlaxoSmithKline0 个研究点目标入组 480 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
480

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • 1. Males/females >= 40 years of age.
  • 2. COPD (all GOLD-stages) diagnosed >= 12 months ago.
  • 3. FEV1/FVC (tiffeneau-index) after use of bronchodilator < 0.70.
  • 4. Smoking history of >= 10 packyears
  • 5. Singed informed consent form.

排除标准

  • 1.In the opinion of the investigator, there is a current primary diagnosis of asthma (patients with a primary diagnosis of COPD but who also have asthma may be included)
  • 2.A diagnosis of fibrosis or asbestosis
  • 3.Diagnosis of cancer - includes current and within the last 5 years (patients in remission for >= 5 years may be included). Patients diagnosed with cancer during the study will be withdrawn
  • 4.Diagnosis of clinically significant bronchiectasis
  • 5.Subjects who are concurrently participating in any clinical study or who have received any investigational drugs within 4 weeks of Visit 1, or who will start any during the study period.
  • 6.Unable to or unwilling to conform with the study requirements including completion of the health status questionnaires
  • 7.Females who are pregnant or lactating.

研究者

相似试验